These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 19139433)

  • 1. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.
    Thomas MB; Morris JS; Chadha R; Iwasaki M; Kaur H; Lin E; Kaseb A; Glover K; Davila M; Abbruzzese J
    J Clin Oncol; 2009 Feb; 27(6):843-50. PubMed ID: 19139433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma.
    Thomas MB; Chadha R; Glover K; Wang X; Morris J; Brown T; Rashid A; Dancey J; Abbruzzese JL
    Cancer; 2007 Sep; 110(5):1059-67. PubMed ID: 17623837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.
    Philip PA; Mahoney MR; Allmer C; Thomas J; Pitot HC; Kim G; Donehower RC; Fitch T; Picus J; Erlichman C
    J Clin Oncol; 2005 Sep; 23(27):6657-63. PubMed ID: 16170173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab and erlotinib in previously untreated inoperable and metastatic hepatocellular carcinoma.
    Govindarajan R; Siegel E; Makhoul I; Williamson S
    Am J Clin Oncol; 2013 Jun; 36(3):254-7. PubMed ID: 22643560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma.
    Sun W; Sohal D; Haller DG; Mykulowycz K; Rosen M; Soulen MC; Caparro M; Teitelbaum UR; Giantonio B; O'Dwyer PJ; Shaked A; Reddy R; Olthoff K
    Cancer; 2011 Jul; 117(14):3187-92. PubMed ID: 21264839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial.
    Hainsworth JD; Spigel DR; Sosman JA; Burris HA; Farley C; Cucullu H; Yost K; Hart LL; Sylvester L; Waterhouse DM; Greco FA
    Clin Genitourin Cancer; 2007 Dec; 5(7):427-32. PubMed ID: 18272024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.
    Herbst RS; Johnson DH; Mininberg E; Carbone DP; Henderson T; Kim ES; Blumenschein G; Lee JJ; Liu DD; Truong MT; Hong WK; Tran H; Tsao A; Xie D; Ramies DA; Mass R; Seshagiri S; Eberhard DA; Kelley SK; Sandler A
    J Clin Oncol; 2005 Apr; 23(11):2544-55. PubMed ID: 15753462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
    Spigel DR; Burris HA; Greco FA; Shipley DL; Friedman EK; Waterhouse DM; Whorf RC; Mitchell RB; Daniel DB; Zangmeister J; Bass JD; Hainsworth JD
    J Clin Oncol; 2011 Jun; 29(18):2582-9. PubMed ID: 21576636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways.
    Sandler A; Herbst R
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4421s-4425s. PubMed ID: 16857821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Spigel DR; Farley C; Thompson DS; Shipley DL; Greco FA;
    J Clin Oncol; 2007 May; 25(13):1747-52. PubMed ID: 17470864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib.
    Hainsworth JD; Sosman JA; Spigel DR; Edwards DL; Baughman C; Greco A
    J Clin Oncol; 2005 Nov; 23(31):7889-96. PubMed ID: 16204015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
    Lin CC; Calvo E; Papadopoulos KP; Patnaik A; Sarantopoulos J; Mita AC; Preston GG; Mita MM; Rodon J; Mays T; Yeh IT; O'Rourke P; Takimoto CH; Dancey JE; Chen H; Tolcher AW
    Cancer Chemother Pharmacol; 2009 May; 63(6):1065-71. PubMed ID: 18795291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
    D'Alessandris QG; Montano N; Cenci T; Martini M; Lauretti L; Bianchi F; Larocca LM; Maira G; Fernandez E; Pallini R
    Acta Neurochir (Wien); 2013 Jan; 155(1):33-40. PubMed ID: 23132371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer.
    Philip PA; Mahoney MR; Holen KD; Northfelt DW; Pitot HC; Picus J; Flynn PJ; Erlichman C
    Cancer; 2012 May; 118(9):2424-30. PubMed ID: 21953248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers.
    Rohrberg KS; Olesen RK; Pfeiffer P; Ladekarl M; Pappot H; Christensen IJ; Høyer-Hansen G; Sørensen M; Skov BG; Buysschaert I; Carmeliet P; Lassen U
    Acta Oncol; 2012 Feb; 51(2):234-42. PubMed ID: 22017239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
    Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB
    J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
    Herbst RS; O'Neill VJ; Fehrenbacher L; Belani CP; Bonomi PD; Hart L; Melnyk O; Ramies D; Lin M; Sandler A
    J Clin Oncol; 2007 Oct; 25(30):4743-50. PubMed ID: 17909199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma.
    Zhu AX; Stuart K; Blaszkowsky LS; Muzikansky A; Reitberg DP; Clark JW; Enzinger PC; Bhargava P; Meyerhardt JA; Horgan K; Fuchs CS; Ryan DP
    Cancer; 2007 Aug; 110(3):581-9. PubMed ID: 17583545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening.
    Simpkins F; Belinson JL; Rose PG
    Gynecol Oncol; 2007 Oct; 107(1):118-23. PubMed ID: 17658587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer.
    Hanna N; Lilenbaum R; Ansari R; Lynch T; Govindan R; Jänne PA; Bonomi P
    J Clin Oncol; 2006 Nov; 24(33):5253-8. PubMed ID: 17114658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.